PURPOSE: To assess the usefulness of 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) of the head and neck in locating occult primary lesions in patients with metastatic cervical adenopathy.

MATERIALS AND METHODS: Seventeen patients with metastatic cervical adenopathy of unknown primary origin were referred for FDG PET of the head and neck. All patients had undergone correlative anatomic imaging within 1 month of FDG PET. Surgical, clinical, and histopathologic findings were used to assess the performance of FDG PET.

RESULTS: Increased apical lung uptake at FDG PET led to a biopsy-proved diagnosis of primary lung cancer in two patients. Of the remaining 15 patients, 10 had a focus of increased activity; directed biopsy of these sites led to confirmation of a primary carcinoma in seven patients. Correlative anatomic imaging failed to demonstrate the primary sites of disease in two of these seven patients. None of the five patients with negative FDG PET studies have manifested evidence of a primary site of disease during follow-up of 8–42 months (mean, 29 months).

CONCLUSION: FDG PET allows effective localization of the unknown primary site of origin in metastatic head and neck cancer and can contribute substantially to patient care.

References

  • 1 Harwick RD. Cervical metastases from an occult primary site. Semin Surg Oncol 1991; 7: 2-8. Crossref, MedlineGoogle Scholar
  • 2 Righi PD, Sofferman RA. Screening unilateral tonsillectomy in the unknown primary. Laryngoscope 1995; 105: 548-550. Crossref, MedlineGoogle Scholar
  • 3 De Braud F, Heilbrun LK, Ahmed K, et al. Metastatic squamous cell carcinoma of an unknown primary localized to the neck: advantages of an aggressive treatment. Cancer 1989; 64: 510-515. Crossref, MedlineGoogle Scholar
  • 4 Maulard C, Houset M, Brunel P, et al. Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma. Laryngoscope 1992; 102: 884-890. Crossref, MedlineGoogle Scholar
  • 5 Som P, Atkins HL, Bandophadhyah D. A fluorinated glucose analogue, 2-[F-18]fluoro-2-deoxy-d-glucose. J Nucl Med 1980; 21: 670-675. MedlineGoogle Scholar
  • 6 Hawkins RA, Hoh CK, Dahlbom M, et al. PET cancer evaluations with 2-[18F]fluoro-2-deoxy-d-glucose. J Nucl Med 1991; 32: 1555-1558. MedlineGoogle Scholar
  • 7 Greven KM, Williams DW, III, Keyes JW, Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74: 1355-1359. Crossref, MedlineGoogle Scholar
  • 8 Rege S, Maass BS, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73: 3047-3058. Crossref, MedlineGoogle Scholar
  • 9 Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Hoh CK, Ward PH. Positron emission tomography: a new precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102: 281-288. MedlineGoogle Scholar
  • 10 Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR 1998; 19: 1189-1196. MedlineGoogle Scholar
  • 11 Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26: 112-115. Crossref, MedlineGoogle Scholar
  • 12 Fu KK. Neck node metastases from unknown primary: controversies in management. Front Radiat Ther Oncol 1994; 28: 66-78. Crossref, MedlineGoogle Scholar
  • 13 Laubenbacher G, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18F-fluorodeoxyglucose PET, MRI, and endoscopy for staging head and neck squamous cell carcinomas. J Nucl Med 1995; 36: 1747-1757. MedlineGoogle Scholar
  • 14 Chaiken L, Rege S, Hoh CK, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 455-464. Crossref, MedlineGoogle Scholar
  • 15 Rege SD, Chaiken L, Hoh CK, et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993; 189: 807-812. LinkGoogle Scholar
  • 16 Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-17. MedlineGoogle Scholar
  • 17 Fu KK, Cooper JS, Marcial VA, et al. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys 1996; 35: 425-438. Crossref, MedlineGoogle Scholar
  • 18 Mukherji SK, Drane WE, Mancuso AA, Parsons JT, Mendenhall WM, Stringer S. Occult primary tumors of the head and neck: detection with 2-[F-18]fluoro-2-deoxy-d-glucose SPECT. Radiology 1996; 199: 761-766. LinkGoogle Scholar
  • 19 Talmi YP, Wolf GT, Hazuka M, Krause CJ. Unknown primary of the head and neck. J Laryngol Otol 1996; 110: 353-356. Crossref, MedlineGoogle Scholar
  • 20 Fidler IJ, Hart LR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 47: 998-1003. Google Scholar
  • 21 Davidson BJ, Spiro RH, Patel S, Patel K, Shah JP. Cervical metastases of occult origin: the impact of combined modality therapy. Am J Surg 1994; 168: 395-399. Crossref, MedlineGoogle Scholar

Article History

Accepted: Aug 24 1998
Received: Mar 02 1998
Revision received: May 05 1998
Revision received: June 08 1998
Published in print: Jan 1999